Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04984876 |
|
Recruitment Status :
Terminated
(Study terminated by sponsor)
First Posted : August 2, 2021
Last Update Posted : March 19, 2024
|
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | August 11, 2023 |
| Actual Study Completion Date : | November 27, 2023 |